μ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer

Anna Cieślińska · Edyta Sienkiewicz-Szlapka · Elżbieta Kostyra · Ewa Fiedorowicz · Jadwiga Snarska · Konrad Wroński · Michał Tenderenda · Beata Jarmołowska · Michał Matysiewicz

Received: 6 November 2014 / Accepted: 14 January 2015 / Published online: 25 January 2015 © The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Structure-dependent μ-opioid receptor (MOR) activity is an important element in cancer opioid analgesic effectiveness. It is widely accepted that guanine (G) substitution for adenine (A) at OPRM1 gene sequence position 118 changes receptor glycosylation pattern. This is associated with decreased binding ability in both exogenous and endogenous opioids, resulting in increased human pain resistance. The endogenous opioid system’s function in body homeostasis maintenance is considered mainly regulatory, so its participation in breast tumor formation and progression is identified herein. We examine the association of the most frequent MOR (A118G) gene polymorphism on breast cancer risk in a Northeastern Polish population by PCR-RFLP comparison of A and G allele frequency at OPRM1 gene A118G polymorphic site in breast cancer-diagnosed patients with healthy control group frequencies. Our results highlight a strong association between G allele presence at μ-opioid receptor A118G and increased breast cancer incidence (OR=3.3, 95 % CI 2.2–5.0, p<0.0001) and female gender (OR=2.0, 95 % CI 1.4–2.9, p=0.0004). Consequently, OPRM1 G allele presence at that site is a highly significant risk factor in breast cancer development.

Keywords Polymorphism · OPRM1 · Breast cancer · μ-Opioid receptor · Opioids

Introduction

The GLOBOCAN 2012 International Agency for Research on Cancer database shows breast cancer (BC) is the most common cancer in females worldwide, at approximately 25 % of all female cancers, and the second most commonly occurring malignancy. It ranks as the fifth major global cause of cancer death and the second in developed countries [1]. It is currently believed that tumor development in the majority of cases is associated with a genetic background, and this includes sporadic tumors [2]. This resulted from increased focus on natural gene population variability as a determinant of cancer susceptibility. At least 80 different genes with 145 variants were investigated to determine the relationship between single nucleotide polymorphisms (SNPs) and breast cancer risk, with polymorphism considered significant in approximately 35 genes with 46 variants [3]. Herein, the previously untested μ-opioid receptor gene (OPRM1) is examined as the newest candidate in this regard.

Opoids form part of the extensive physiological system of neuronal, hormonal, and immune regulation essential for bodily homeostasis maintenance. Their pain perception control and analgesia is moderated by endogenous and exogenous...
opioid peptide interaction with receptors situated in the central and peripheral nervous systems, in the immunologic system, and on the endothelial cell surface [4–7].

While opioid influence on tumor growth and cancer progression is less established, there is increasing evidence for its support [8–13]. μ-Opioid receptor (MOR) expression in breast cancer cells has been demonstrated in both the MCF-7 and T47D ER-positive BC cell lines and in patient biopsy specimens [14–17]. Chatikhine and coworker’s immunohistochemical studies [18] showed that the most common type of BC invasive ductal carcinomas can prove positive for β-endorphin and Met-enkephalin opioid peptides [18]. Further research has revealed that clinically relevant doses of analgesic opioids, such as morphine, promote basal cell proliferation and migration, and accompanying angiogenesis results in direct tumor growth and metastasis [9, 19, 20] or in indirect morphine-induced immunosuppression [13]. In contradistinction, however, morphine and other opioids also promote tumor cell death [15, 16, 21]. While these facts suggest that the endogenous opioid system can participate in breast cancer development and progression, many results on opioid and BC interrelationships are contradictory. One reason for this discord may be genetic variation in the OPRM1 gene.

The human OPRM1 gene is located on chromosome 6q24–q25. It spans 236 kb with at least 11 exons and 17 different splice variants under the control of multiple promoters [22]. The most commonly occurring MOR polymorphism is A118G variant (rs1799971). This is located in the first exon of gene and consists of non-synonymous substitution of guanine (G) for adenine (A), resulting in the exchange of aspartic acid for asparagine at MOR protein position 40 (N40D). This leads to loss of the N-glycosylation site in the G protein-coupled receptor’s extracellular region and associated change in its molecular level function [23]. Clinical observations have demonstrated a relationship between A118G polymorphism frequency and response to exogenous opioids, with resultant pain threshold variation [24–28]. Further studies suggest that G allele carriers exhibit decreased breast cancer-specific mortality [29] and significantly lowered risk of esophageal carcinoma development [30].

Our previous research identified opioid peptides in lactating women’s milk, where concentrations of cryptopeptides derived from human β-casein β-casomorphin-5 and β-casomorphin-7 were dependent on lactation phase [31]. This result combined with lactation as a protective factor in breast cancer risk and the abovementioned opioid participation in tumor biology prompted our examination of the relationship between the A118G polymorphism in the OPRM1 μ-opioid receptor gene and breast cancer occurrence.

Patients and methods

Patients and control group characteristics

Our study subjects were 151 recently diagnosed female breast cancer patients recruited at the Department of General Surgery and Oncology of the Warmia and Mazury University Hospital and at the General and Oncologic Surgery Wards of the Warmia and Mazury Oncology Centre in Olsztyn in 2013–2014. The contraindications for research qualification were breast cancer recurrence after previous surgery, metastasized cancer from other organs, and/or previous radiotherapy or chemotherapy. The control group consisted of 590 unrelated volunteers recruited on the basis of the screening at the abovementioned departments and at the University Health Center in Olsztyn who had not reported of any type of cancer, infectious disease, or surgery for at least 3 years prior to recruitment. Both experimental and control group members reported a history of no opioid drug use. All participants gave informed consent and data was collected from their medical records and/or a completed questionnaire. Each person supplied peripheral blood as research material, and all investigation procedures accorded with ethical standards and were approved by the Local Bioethics Committee (permit number: OIL.492/12/Bioet).

Sample genotyping

Participant’s 2-mL peripheral venous blood samples were collected in Vacutainer EDTA tubes, marked with individual ID code, and transported to the laboratory in blind case-control status. Genomic DNA was isolated from whole blood using GeneJET™ Whole Blood Genomic DNA Purification Mini Kit (Thermo Scientific) according to the manufacturer’s instructions and stored at −80 °C prior to genotyping. The selection of the OPRM1 PCR reaction primers was based on Romberg et al.’s publication [32], with the following sequences: Oprm1F-5′-GGTCAACTTGTCCACTTAGAT CGC-3′ and Oprm1R-5′-AATCACATACATGACCA GGAAGTTT-3′.

PCR amplification was conducted in a thermal cycler according to the following conditions: initial denaturation at 94 °C for 3 min, followed by 40 cycles of 30 s at 94 °C complete denaturation, 30 s at 61 °C for starter attachments, 30 s synthesis at 72 °C, and final elongation at 72 °C for 5 min. The 25-μL mixture volume comprised DreamTaq™ Green Master Mix (Thermo Scientific), specific starters, the DNA matrix, and molecularly pure water (Sigma-Aldrich). The PCR product yield and specificity were evaluated by electrophoresis in 1.5 % agarose gel (Promega) stained with GelGreen (Biotium). The PCR products were then digested with FastDigest® Bsh1236I restriction enzyme (Thermo Scientific) according to the manufacturer’s instructions, separated...
on 2.5 % agarose gel, and identified by GelGreen (Biotium) staining. Genotyping was confirmed by the DNA sequencing of random chosen samples.

Statistical analysis

The frequency distribution of common risk factors for BC, including age, menstrual and menopausal history, age at menarche and at first child birth, breast-feeding, family history of BC, and smoking, was examined in our study population by the Pearson χ² test or by the Mann–Whitney U test. The genotype distribution among subjects was analyzed for Hardy–Weinberg equilibrium (HWE) using the chi-square test, and genotype and SNP allele frequencies were compared in cancer patients and control groups by Fisher’s test. Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated using logistic regression analysis and used to compare both allele frequencies in cancer patients and healthy controls, and allele frequencies between female and male. The risk of breast cancer development was estimated via variant GG and AG genotype comparison with the wild-type AA homozygote. Statistical analysis was conducted on GraphPad Prism software (v 6.01; San Diego, CA, USA), with a p value ≤0.05 considered statistically significant.

Results

The study population consisted of 151 histopathologically confirmed breast cancer patients and 590 healthy controls (287 female and 303 male). The distribution of selected characteristics in breast cancer females and healthy volunteers is listed in Table 1, with no statistically significant differences in the majority of compared features. All subjects were Caucasians, of approximately the same age. Both healthy and breast cancer female groups (HF and BCF, respectively) had similar fertility rates, and they reached sexual maturity, menopausal status, and gave birth at equivalent ages. Most HF and BCF were breast-fed, with a slightly less percent in the BCF group. While 10 % of both groups were nulliparous, more BC females were postmenopausal (p=0.03) and more were smokers (p=0.03). In addition, while both female groups, and only a few more BC than HF, reported a positive breast cancer family history, healthy males recorded BC occurrence in their female relatives twice less frequently (p=0.02). Clinical evidence and histopathology classified all BCs herein invasive, with 58 % in stage I and 42 % in stage II (data not shown).

The observed genotype distribution of OPRM1 A118G polymorphism in both control subgroups and cancer patients conformed to the Hardy–Weinberg equilibrium (p>0.05). This suggests no population stratification and no sampling bias. The AA, AG, and GG genotypes were identified, with 0.1 G allele frequency in the entire research population. Of the total 741 participants, 609 had genotype AA, 119 had AG, and 13 had GG. These latter 13 GG genotypes were in 5 healthy individuals and 8 cancer-diagnosed patients. All healthy GG homozygous carriers were females under 50 years of age, and 3 of these were premenopausal. The AG genotype was present in 75 healthy control individuals and 44 BC patients. The respective genotype distribution and A/G allele frequencies are listed in Table 2.

Our results suggest a strong association between the presence of the G allele at position 118 of the μ-opioid receptor gene and increased breast cancer incidence (OR=3.3, 95 % CI 2.2–5.0, p<0.0001). Significant difference was also identified in G allele occurrence in the female gender (OR=2.0, 95 % CI 1.4–2.9, p=0.0004).

Discussion

Although the endogenous opioid system’s precise role in tumor initiation and development remains undetermined, a relationship with cancer is anticipated because it plays a regulatory function in organism homeostasis, and opioid peptides and receptors are present in cancer cells [14, 17, 18]. The identification of functionally significant genetic variation in the opioid system compounds this issue. Global reports indicate that OPRM1 A118G allele frequencies are highly dependent on ethnicity, where the overall G allelic frequency varies between 0.8 and 48 % in different ethnic groups [23]. Genotypic distribution analysis of our entire population identified 10 % G allele frequency, thus approximating the established global Caucasian frequency of 11–17 % [23].

Herein, we investigated the association between A118G OPRM1 gene polymorphism and breast cancer risk. We found that female G allele carriers had more than three times increased breast cancer risk than both healthy female and the entire control group. The one previous study on the relationship between A118G OPRM1 gene and breast cancer by Bortsov et al. recorded that breast cancer-specific mortality was significantly reduced in patients possessing the OPRM1 118G variant allele [29]. Additionally, while the protective effect of this SNP was limited only to invasive cases, it increased with increasing cancer diagnosis stage. These authors concluded this was due to reduced opioid response in patients who possessed one or both G alleles. In contrast, we examined only primary invasive breast cancer patients with no history of opioid use. The μ-opioid G variant receptor may therefore play a protective role by decreasing opioid drug action in cancer progression and metastasis, and simultaneously increase the risk of endogenous opioid peptide action in the carcinogenic process. Mura et al.’s [23] summary of research into the molecular consequences of A118G OPRM1 polymorphism indicates that this phenomenon is possible because, in
contrast to the wild-type A variant N40 receptor effect, the G
variant receptor can be associated with both decreased and
increased signal transduction. It is important to note here that
females can also be influenced by β-casomorphin-5 and β-
casomorphin-7 opioid peptides in lactation milk. While both
β-casomorphin peptide concentrations changed with lactation
phase in healthy breast-feeding females [31], concentrations
remained the same throughout lactation in the breast milk of
females with food allergies [33]. While this expected time-
dependent β-casomorphin gradient in healthy lactating fe-
males inspires a comparative study of the interrelationships
between breast-feeding period, respective genotypes, and
breast cancer diagnosis, our current study group has inappro-
priate stratification to pursue this herein. Future research will
establish study population stratification which identifies inter-
relationships between the number of live births, maternal lac-
tation duration, feeding periods, and food allergy status.
Mainstream clinical A118G OPRM1 polymorphism analysis
focuses on opioid-induced analgesia and opioids, vulner-
ability to alcohol and nicotine addiction, and therapy re-
sponse. It is interesting here that our female OPRM1 G allele
frequency is approximately twice that of males. No males
were GG homozygous and only 40 carried one G allele. Some
studies indicate gender-specific associations [34–36], and
Fillingim et al.’s allelic distribution of tested SNP in healthy
people specifies only females [28]. Although these authors’
population was more ethnically diverse than ours, their G
allele overrepresentation in females is consistent with our re-
sults. This may constitute one explanation why breast cancer
is so rare in males; accounting for only 0.6 % of all breast
cancer patients worldwide [37]. It is acknowledged that male
BC does not significantly differ from female BC, except in
obvious gender-specific differences, and also that breast can-
cer is more likely to be estrogen receptor (ER)-positive in

Table 1 Distribution of selected characteristics in breast cancer
patients and healthy individuals

| Characteristics                          | Control | Breast cancer female (BCF) | p value* |
|------------------------------------------|---------|---------------------------|----------|
|                                           | Healthy male (HM) | Healthy female (HF)       | (BCF vs. HF/BCF vs. HM) |
|                                           | n=303   | n=287                     |          |
| Age (years), mean (SD)                   | 49.8 (12.4) | 53.3 (26.2)              | 0.93/0.28 |
| Age of menarche (years), mean (SD)       | n.a.    | 13.3 (1.1)                | 0.35     |
| Age of first birth (years)b, mean (SD)   | n.a.    | 26.1 (3.5)                | 0.35     |
| Number of live birthsc, mean (SD)        | n.a.    | 1.8 (0.6)                 | 0.62     |
| Age at menopause (years)c, mean (SD)     | n.a.    | 48.3 (2.4)                | 0.27     |
| Postmenopausal status, %                 | n.a.    | 88.2                      | 0.03     |
| Breast-feedingb, %                      | n.a.    | 80.1                      | 0.13     |
| Nulliparous, %                          | n.a.    | 9.8                       | 0.78     |
| Positive family history of BC, %         | 8.5     | 13.6                      | 0.31/0.02 |
| Smoking, %                              | 34.8    | 28.3                      | 0.03/0.72 |
| Ethnicity (Caucasian race), %            | 100     | 100                       | 1.00/1.00 |

CI confidence interval, OR odds ratio
a OR adjusted for age, age of menarche and menopause, age of
first birth, number of live births, breast-feeding, postmenopausal
status, family history of cancer, and smoking status
b OR adjusted for age, family history of cancer, and smoking status
c Among 135 parous BC cases and 259 parous controls

Table 2 Genotype and allele frequencies of OPRM1 gene
A118G polymorphism in studied groups and G allele breast cancer
association

| Research group | % of genotypes | Frequency of alleles |
|----------------|----------------|---------------------|
|                | AA | AG | GG | A | G |                  |
| Control group  | 86.4 | 12.7 | 0.9 | 0.93 | 0.07 |
| Healthy male   | 86.8 | 13.2 | 0.0 | 0.91 | 0.09 |
| Studied female | 79.0 | 18.0 | 3.0 | 0.88 | 0.12 |
| Healthy female | 86.1 | 12.8 | 1.7 | 0.92 | 0.08 |
| Breast cancer female | 65.6 | 29.1 | 5.3 | 0.80 | 0.20 |

OR (95 % CI), p value

| p value* |
|----------|
|<0.0001 |
|<0.0001 |
| 0.0004 |
| 0.42    |
males than in females [38]. It should be noted that functional relationship between ERs and MOR has been reported recently. It was shown that MOR activation leads to ERα activation and mediates its translocation to the plasma membranes. The synergistic induction of breast cancer cell proliferation has been observed as the final effect [39]. Moreover, it has also been shown that expression of ERβ can be regulated by opioids [40]. In conclusion, since the MOR G allele (40D variant) proves more sensitive to endogenous opioid peptides and promotes the recently reported estrogen receptor interaction, our results highlight the significance of the OPRM1 G allele as a serious risk factor in breast cancer development.

Conflicts of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. GLOBOCAN 2012 (IARC). Breast cancer: estimated incidence, mortality and prevalence worldwide in 2012. Lyon, France. International Agency for Research on Cancer. 2013. http://globocan.iarc.fr. Accessed 28 Jul 2014.

2. Gronwald J, Byrski T, Huzarski T, Oszurek O, Janicka A, Szymańska-Pasternak J, et al. Hereditary breast and ovarian cancer. Postepy Nauk Med. 2008;7:446–55.

3. Peng S, Lu B, Ruan W, Yimin Zhu Y, Sheng H, Lai M. Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies. Breast Cancer Res Treat. 2011;127:309–24.

4. Goody RJ, Kitchen I. Influence of maternal milk on functional activation of δ-opioid receptors in postnatal rats. J Pharmacol Exp Ther. 2001;296(3):744–8.

5. Kieffer BL, Gavériaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol. 2002;66(5):285–306.

6. Campana G, Sarti D, Spampinato S, Raffaelli W. Long-term intraclinical morphine and bupivacaine upregulate MOR gene expression in lymphocytes. Int Immunopharmacol. 2010;10:1149–52.

7. Cadet P, Mantione K, Bilfinger TV, Stefano GB. Morphine down regulates human vascular tissue estrogen receptor expression determined by real time PCR. Neuroendocrinol Lett. 2002;23:95–100.

8. Hatzoglou A, Ouafik L, Bakogeorgou E, Thermos K, Castanas E. The antiproliferative effect of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro. Peptides. 2010;31:1606–12.

9. Azarzadeh, M M, Fatemeh, A, Lipkowski AW. A comparative study of morphine stimulation and buphalin inhibition of human glioblastoma T98G cell proliferation in vitro. Peptides. 2010;31:1606–12.

10. Mathew B, Lennon FE, Siegler J, Mirzapozaitova T, Mambetsariiev N, Sammani S, et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011;112(3):558–67.

11. Gach K, Wyrębska A, Fichna J, Janecka A. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs’ Arch Pharmacol. 2011;384(3):221–30.

12. Mathew B, Lennon FE, Siegler J, Mirzapozaitova T, Mambetsariiev N, Sammani S, et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011;112(3):558–67.

13. Gach K, Wyrębska A, Fichna J, Janecka A. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs’ Arch Pharmacol. 2011;384(3):221–30.

14. Gach K, Piestrzyniewicz M, Fichna J, Stefanska B, Szemraj J, Janecka A. Opioid-induced regulation of μ-opioid receptor gene expression in the MCF-7 breast cancer cell line. Biochem Cell Biol. 2008;86(3):217–26.

15. Hatzoglou A, Bakogeorgou E, Castanas E. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line is partially mediated through opioid receptors. Eur J Pharmacol. 1996;296:199–207.

16. Maneckjee R, Biswas R, Vonderhaar BK. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res. 1990;50:2234–8.

17. Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE. Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst. 1987;79:1059–65.

18. Chatikhine VA, Chevrier A, Chauzy C, Duval C, d’Anjou J. Expression of opioid peptides in cells and stroma of human breast cancer and adenofibromas. Cancer Lett. 1994;7:51–6.

19. Gach K, Szemraj J, Fichna J, Piestrzyniewicz M, Delbro DS, Janecka A. The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line. Chem Biol Drug Des. 2009;74:390–6.

20. Gach K, Szemraj J, Wyrębska A, Janecka A. The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line. Mol Biol Rep. 2011;38:1231–6.

21. Sueoka E, Sueoka N, Kai Y, Okabe S, Saganuma M, Kanematsu M, et al. Anticancer activity of morphine and its synthetic derivative, KT-90, mediated through apoptosis and inhibition of NF-kappaB activation. Biochem Biophys Res Commun. 1998;252:566–70.

22. Kasai S, Ikeda K. Pharmacogenomics of the human μ-opioid receptor. Pharmacogenomics. 2011;12:1305–20.

23. Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, et al. Consequences of the 118A>G polymorphism of the OPRM1 gene: translation from bench to bedside? J Pain Res. 2013;6:331–53.

24. Klepstad P, Rakvag TT, Kaasa S, Holte M, Dale O, Borchgrevink PC, et al. The 118A/G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48:1232–9.

25. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand. 2006;50:787–92.

26. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lutsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther. 2003;73:107–21.

27. Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I. How individual sensitivity to opioids can be predicted by gene analyses. Trends Pharmacol Sci. 2005;26:311–7.

28. Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, Campbell CM, et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain. 2005;6:159–67.

29. Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA. μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology. 2012;116(4):896–902.

30. Wang S, Li Y, Liu X-D, Zhao C-Z, Yang K-Q. Polymorphism of A118G in u-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol. 2013;18(4):666–9.
31. Jarmołowska B, Sidor K, Iwan M, Bielikowicz K, Kaczmarski M, Kostyra E, et al. Changes of β-casomorphin content in human milk during lactation. Peptides. 2007;28:1982–6.

32. Romberg RR, Olofsen E, Bijl H, Taschner PE, Teppema LJ, Sarton EY, et al. Polymorphism of mu-opioid receptor gene (OPRM1: c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology. 2005;102(3):522–30.

33. Sidor K, Jarmołowska B, Kaczmarski M, Kostyra E, Iwan M, Kostyra H. Content of β-casomorphins in milk of women with a history of allergy. Pediatr Allergy Immunol. 2008;9(7):587–91.

34. Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K, et al. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology. 2006;188:355–63.

35. Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J. 2007;7:353–61.

36. Kim SG. Gender differences in the genetic risk for alcohol dependence—the results of a pharmacogenetic study in Korean alcoholics. Nihon Arakoru Yakubutsu Igakkai Zasshi. 2009;44:680–5.

37. Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Laronningen S, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol. 2011;29:4381–6.

38. Greif JM, Pezzi CM, Klimberg VS, Bailey L, Zuraek M. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol. 2012;19(10):3199–204.

39. Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther. 2006;5(3):611–20.

40. Cadet P, Bilfinger TV, Fimiani C, Peter D, Stefano GB. Human vascular and cardiac endothelia express mu opiate receptor transcripts. Endothelium. 2000;7(3):185–91.